New crystalline form of enavogliflovine and its preparation process

MA71281B1Active Publication Date: 2026-06-30DAEWOONG PHARM CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
MA71281
Authority / Receiving Office
MA · MA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2023-09-27
Filing Date
2023-09-27
Publication Date
2026-06-30
Estimated Expiration
2043-09-27
Patent Text Reader

Abstract

<pre>The present invention relates to a novel crystalline form of enavogliflozin and its preparation process. The novel crystalline form of enavogliflozin, according to the present invention, has superior thermodynamic stability and hygroscopic properties compared to a conventional crystalline form of enavogliflozin, and thus exhibits excellent long-term storage capacity and pharmaceutical stability. Furthermore, the time to Cmax is shorter than that of the conventional crystalline form of enavogliflozin, allowing for rapid drug effects and thus enabling the efficient use of the present invention.< / pre>
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Pharmaceutical composition comprising sglt-2 inhibitor for preventing or treating diabetic opthalmopathy disease

    KR102427225B1

  • Novel diphenylmethane derivatives as SGLT2 inhibitors

    WO2012165914A2

  • Method for producing diphenylmethane derivative

    WO2017217792A1

  • Method for producing diphenylmethane derivative

    WO2018004202A1